The FDA changed its stance and told Moderna that it would reconsider its application for approval of a new mRNA-based flu vaccine, which it had declined to review in early February 2026[1]. Initially, the FDA rejected Moderna's application on the grounds that the manufacturer "refused to follow FDA's clear 2024 guidance and test its product in a clinical trial with a CDC-recommended flu vaccine to compare safety and efficacy"[1]. Moderna subsequently requested a meeting with the FDA after receiving a letter denying its application[1]. This situation concerns mRNA technology, which was key to the rapid development of vaccines against COVID-19 during the pandemic[1]. The FDA's decision to reevaluate the application represents a change in the US regulatory agency's stance toward this Moderna project.